These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 31503486)

  • 21. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
    Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
    J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functionalized 1,2,3-triazolium salts as potential agents against visceral leishmaniasis.
    das Chagas Almeida A; Meinel RS; Leal YL; Silva TP; Glanzmann N; Mendonça DVC; Perin L; Cunha-Júnior EF; Coelho EAF; Melo RCN; da Silva AD; Coimbra ES
    Parasitol Res; 2022 May; 121(5):1389-1406. PubMed ID: 35169883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
    Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
    J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
    J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis.
    Valadares DG; Duarte MC; Ramírez L; Chávez-Fumagalli MA; Martins VT; Costa LE; Lage PS; Ribeiro TG; Castilho RO; Fernandes AP; Régis WC; Soto M; Tavares CA; Coelho EA
    Exp Parasitol; 2012 Oct; 132(2):228-36. PubMed ID: 22824583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
    Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis.
    Bhattacharjee A; Majumder S; Majumdar SB; Choudhuri SK; Roy S; Majumdar S
    Int J Antimicrob Agents; 2015 Mar; 45(3):268-77. PubMed ID: 25600891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum.
    Buffet PA; Garin YJ; Sulahian A; Nassar N; Derouin F
    Ann Trop Med Parasitol; 1996 Jun; 90(3):295-302. PubMed ID: 8758143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.
    da Costa-Silva TA; Galisteo AJ; Lindoso JA; Barbosa LR; Tempone AG
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
    Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
    Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nanodelivered Vorinostat derivative is a promising oral compound for the treatment of visceral leishmaniasis.
    Corpas-López V; Díaz-Gavilán M; Franco-Montalbán F; Merino-Espinosa G; López-Viota M; López-Viota J; Belmonte-Reche E; Pérez-Del Palacio J; de Pedro N; Gómez-Vidal JA; Morillas-Márquez F; Martín-Sánchez J
    Pharmacol Res; 2019 Jan; 139():375-383. PubMed ID: 30503838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nicotinamide mitigates visceral leishmaniasis by regulating inflammatory response and enhancing lipid metabolism.
    Zhou Q; Zheng Z; Yin S; Duan D; Liao X; Xiao Y; He J; Zhong J; Zeng Z; Su L; Luo L; Dong C; Chen J; Li J
    Parasit Vectors; 2024 Jul; 17(1):288. PubMed ID: 38971783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.
    Faraut-Gambarelli F; Piarroux R; Deniau M; Giusiano B; Marty P; Michel G; Faugère B; Dumon H
    Antimicrob Agents Chemother; 1997 Apr; 41(4):827-30. PubMed ID: 9087498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis.
    Romanelli MM; da Costa-Silva TA; Cunha-Junior E; Dias Ferreira D; Guerra JM; Galisteo AJ; Pinto EG; Barbosa LRS; Torres-Santos EC; Tempone AG
    Front Cell Infect Microbiol; 2019; 9():353. PubMed ID: 31737574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
    Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
    J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An adamantamine derivative as a drug candidate for the treatment of visceral leishmaniasis.
    Pomel S; Cojean S; Pons V; Cintrat JC; Nguyen L; Vacus J; Pruvost A; Barbier J; Gillet D; Loiseau PM
    J Antimicrob Chemother; 2021 Sep; 76(10):2640-2650. PubMed ID: 34212184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finding of leishmanicidal activity of 14-hydroxylunularin in mice experimentally infected with Leishmania infantum.
    Serna ME; Maldonado M; Torres S; Schinini A; Lima AP; Pandolfi E; de Arias AR
    Parasitol Int; 2015 Oct; 64(5):295-8. PubMed ID: 25843766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection mediated by chemokine CXCL10 in BALB/c mice infected by Leishmania infantum.
    Figueiredo WME; Viana SM; Alves DT; Guerra PV; Coêlho ZCB; Barbosa HS; Teixeira MJ
    Mem Inst Oswaldo Cruz; 2017 Aug; 112(8):561-568. PubMed ID: 28767981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.